Current Anticoagulant Therapy for Venous Thromboembolism

Mashio Nakamura; Norikazu Yamada; Masaaki Ito

doi:10.7134/phlebol.16-06

January 1, 2016The Japanese Journal of PhlebologyOpen Access

Current Anticoagulant Therapy for Venous Thromboembolism

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Do NOACs/DOACs and fondaparinux improve efficacy and safety compared to conventional anticoagulants in patients with venous thromboembolism?

Structured PICO

Do NOACs/DOACs and fondaparinux improve efficacy and safety compared to conventional anticoagulants in patients with venous thromboembolism?

P

Population

Patients with venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE)

I

Intervention

Non-vitamin K antagonist oral anticoagulants (NOACs) / direct oral anticoagulants (DOACs) including edoxaban, rivaroxaban, apixaban, and the parenteral factor Xa inhibitor fondaparinux

C

Comparator

Conventional anticoagulant therapy (unfractionated heparin followed by warfarin)

O

Outcome

VTE recurrence and bleeding complications

Limitations

Lack of established evidence for optimal dosing and safety in highly fragile patients (e.g., elderly, low body weight, renal impairment)
Optimal duration of long-term therapy remains to be fully established

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

NOACs/DOACs provide a safer, more convenient, and effective alternative to conventional heparin and warfarin therapy for the acute and long-term management of VTE.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nakamura et al. (2016) studied this question.

synapsesocial.com/papers/6a765ed4e2126634eb1b539f https://doi.org/10.7134/phlebol.16-06

View Full Paper

Ask AI

Bookmark

Share

Current Anticoagulant Therapy for Venous Thromboembolism

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Current Anticoagulant Therapy for Venous Thromboembolism

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading